Faran Shimi Pharmaceutical Company was established in 2002 as a production cooperative in the Tuyserkan Industrial Zone. The company began its operations with the production of salicylic acid and joined the Golrang Industrial Group in 2007, followed by its integration into Golrang Pharmaceutical Investment Holding in 2010.

By leveraging four key pillars—management, financial strength, scientific expertise, and operational capabilities—Faran Shimi Pharmaceutical Company has experienced rapid growth and successfully developed its considerable potential. With its substantial production capacity, the company currently employs more than 350 professionals, a figure expected to increase to 500 employees with the launch of new production lines.

Faran Shimi Pharmaceutical Company operates through two main divisions: the production of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). In the field of API manufacturing, the company focuses on two main categories based on production volume and value addition: low-volume, high-value (LVHV) products and medium-volume (mass-market) products.

The company’s portfolio includes more than 20 pharmaceutical molecules, offering a range of therapeutic solutions for pain management, opioid use disorder, diabetes, coagulation disorders, cough, and pulmonary arterial hypertension. We remain committed to delivering the highest quality products, contributing to the improvement of public health, and standing alongside patients throughout their treatment journey.

Faran Shimi Pharmaceutical Company is active across a wide range of therapeutic areas, including opioid-related treatments, pain management, respiratory diseases, multiple sclerosis (MS), and internal medicine. The company is also expanding its activities into broader therapeutic fields in the near future.